Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia (PERIOSTINE)

Civil Hospices of Lyon

Status: Completed

Conditions: Bone Fibrous Dysplasia

Treatments: Biological: Blood sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT02868645

69HCL15_0336

Details and patient eligibility

About

Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been shown that periostin is over expressed in fibrous component in patients bones ; but periostin has never been measured out in serum of patients, although it is easy to assess. This study aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia, and if it is more elevated in patients with severe forms of the disease.

Enrollment: 65 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients with fibrous dysplasia of the bone
• access to social security
• informed consent

Exclusion criteria

• no informed consent
• pregnancy
• patients with a history of conditions known to increase periostin serum (stade IV cancer, severe asthma, pulmonary fibrosis…)

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

65 participants in 2 patient groups

Patients with bone fibrous dysplasia

Experimental group

Description:

Patients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum

Treatment:

Biological: Blood sampling

Control subjects

No Intervention group

Description:

Control subjects will have no intervention